to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia

PHASE4CompletedINTERVENTIONAL
Enrollment

313

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
HbA1c Level Associated With Lipid Compositions
Interventions
DRUG

Pitavastatin calcium 4mg

taking once a day

DRUG

Pitavastatin calcium 2mg

Taking once a day

Trial Locations (1)

137-864

JW pharmaceutical, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

The Catholic University of Korea

OTHER

collaborator

Kyunghee University Medical Center

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Dong-A University Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Ajou University School of Medicine

OTHER

collaborator

Gangnam Severance Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Yeungnam University Hospital

OTHER

collaborator

Ulsan University Hospital

OTHER

collaborator

Eulji University Hospital

OTHER

collaborator

Asan Medical Center

OTHER

collaborator

Chonnam National University Hospital

OTHER

collaborator

Chonbuk National University Hospital

OTHER

collaborator

Chungnam National University Hospital

OTHER

collaborator

Hallym University Medical Center

OTHER

lead

JW Pharmaceutical

INDUSTRY

NCT02056847 - to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia | Biotech Hunter | Biotech Hunter